Search results
Results from the WOW.Com Content Network
The following are settlements reached with US authorities against pharmaceutical companies to resolve allegations of "off-label" promotion of drugs. Under the Federal Food, Drug, and Cosmetic Act, it is illegal for pharmaceutical companies to promote their products for uses not approved by the Food and Drug Administration (FDA), and corporations that market drugs for off-label indications may ...
During its 2007 Q2 earnings conference, AstraZeneca announced plans to launch Seroquel XR in the U.S. during August 2007. [91] However, Seroquel XR has become available in U.S. pharmacies only after the FDA approved Seroquel XR for use as maintenance treatment for schizophrenia, in addition to acute treatment of the illness, on 16 November 2007 ...
Seroquel: False Claims Act 2007 Bristol-Myers Squibb [18] $515 million Off-label promotion, kickbacks, Medicare fraud Abilify, Serzone: False Claims Act, FDCA 2002 Schering-Plough [19] $500 million Poor manufacturing practices Claritin: FDA Current Good Manufacturing Practices: 2006 Mylan [20] $465 million Misclassification under the Medicaid ...
Still, the suit focused on diabetes, and the complaint Sheller wrote was a hodgepodge of weak claims, in large part because the boy had also taken the Risperdal competitor drug Seroquel. Its manufacturer, AstraZeneca, was also named as a defendant, as was the boy’s doctor, who was accused of malpractice.
AstraZeneca (AZN) told American doctors the company's antipsychotic drug Seroquel. Skip to main content. Sign in. Mail. 24/7 Help. For premium support please call: 800-290-4726 more ...
Seroquel: AstraZeneca [15] $520,000,000 $520 million (civil only) Off-label promotion/kickbacks False Claims Act 2007 12 11 Abilify/Serzone: Bristol-Myers Squibb [16] $540,000,000 $515 million ($25 million in civil disgorgement) Off-label promotion/ kickbacks/Medicare fraud False Claims Act/FDCA 2016 14 (tie) 12 EpiPen (epinephrine) Mylan [17 ...
Several other lawsuits have been filed by major drug makers and groups including Johnson & Johnson , Merck & Co and AstraZeneca. A judge recently heard arguments in AstraZeneca's case.
In April 2010, AstraZeneca settled a qui tam lawsuit brought by Stefan P. Kruszewski for US$520 million to settle allegations that the company defrauded Medicare, Medicaid, and other government-funded health care programs in connection with its marketing and promotional practices for the blockbuster atypical antipsychotic, Seroquel. According ...